低级别胶质瘤生存列线图的独立验证
本研究基于TCGA与OBTS数据,针对新诊断低级别胶质瘤(WHO II、III级)患者开发并独立验证生存列线图,纳入肿瘤分级、年龄、性别、KPS及分子分型等变量,采用Cox回归、随机生存森林和递归分割分析建模。最终列线图经外部校准曲线验证,II级肿瘤、较年轻、高KPS及IDH突变伴1p/19q共缺失与更高生存概率相关。
要点
- 列线图可个体化估算新诊断低级别胶质瘤患者的生存概率。
- II级肿瘤、较年轻、高KPS及IDH突变伴1p/19q共缺失提示生存概率更高。
- 提供免费在线软件便于临床医生使用该列线图。
核心结论
- 新诊断低级别胶质瘤的生存列线图已开发并完成外部验证,可辅助治疗决策与患者咨询。
研究设计与样本
- 数据来自TCGA(建模)与OBTS(独立外部验证)的新诊断低级别胶质瘤患者,变量包括肿瘤分级、诊断年龄、性别、KPS和分子亚型。
- 采用Cox比例风险回归、随机生存森林和递归分割分析建模,并用10折交叉验证及校准曲线评估。
- 研究类型为预后模型开发与独立验证研究。
主要发现
- 最终列线图在新诊断低级别胶质瘤中得到验证,可计算个体化生存概率。
- 提高生存概率的因素包括II级肿瘤、较年轻诊断年龄、高KPS及IDH突变伴1p/19q共缺失分子亚型。
关键数值与推荐
- 纳入变量:肿瘤分级(II或III级)、诊断年龄、性别、KPS、分子亚型(IDH突变伴1p/19q共缺失、IDH突变不伴1p/19q共缺失、IDH野生型)。
- 内部验证采用10折交叉验证,外部验证采用校准曲线。
- 在线工具地址:https://hgittleman.shinyapps.io/LGG_Nomogram_H_Gittleman/。
临床怎么用
- 可用于新诊断低级别胶质瘤患者的个体化生存估算,辅助治疗决策与患者沟通。
- 临床医生可通过提供的免费在线软件直接使用该列线图。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gliomas are the most common primary malignant brain tumor. Diffuse low-grade and intermediate-grade gliomas, which together compose the lower-grade gliomas (LGGs; World Health Organization [WHO] grades II and III), present a therapeutic challenge to physicians due to the heterogeneity of their clinical behavior. Nomograms are useful tools for individualized estimation of survival. This study aimed to develop and independently validate a survival nomogram for patients with newly diagnosed LGG. METHODS: Data were obtained for newly diagnosed LGG patients from The Cancer Genome Atlas (TCGA) and the Ohio Brain Tumor Study (OBTS) with the following variables: tumor grade (II or III), age at diagnosis, sex, Karnofsky performance status (KPS), and molecular subtype (IDH mutant with 1p/19q codeletion [IDHmut-codel], IDH mutant without 1p/19q codeletion, and IDH wild-type). Survival was assessed using Cox proportional hazards regression, random survival forests, and recursive partitioning analysis, with adjustment for known prognostic factors. The models were developed using TCGA data and independently validated using the OBTS data. Models were internally validated using 10-fold cross-validation and externally validated with calibration curves. RESULTS: A final nomogram was validated for newly diagnosed LGG. Factors that increased the probability of survival included grade II tumor, younger age at diagnosis, having a high KPS, and the IDHmut-codel molecular subtype. CONCLUSIONS: A nomogram that calculates individualized survival probabilities for patients with newly diagnosed LGG could be useful to health care providers for counseling patients regarding treatment decisions and optimizing therapeutic approaches. Free online software for implementing this nomogram is provided: https://hgittleman.shinyapps.io/LGG_Nomogram_H_Gittleman/. KEY POINTS: 1. A survival nomogram for lower-grade glioma patients has been developed and externally validated.2. Free online software for implementing this nomogram is provided allowing for ease of use by practicing health care providers.
引用
- Gittleman H, Sloan AE, Barnholtz-Sloan JS, et al. An independently validated survival nomogram for lower-grade glioma. Neuro Oncol. 2020. PMID: 31621885. doi:10.1093/neuonc/noz191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。